Ptc Therapeutics (PTCT) EBIT Margin (2012 - 2026)

Ptc Therapeutics' EBIT Margin history runs 15 years deep, the most recent figure standing at 16.5% for Q1 2026.

• On a quarterly basis, EBIT Margin fell 6600.0% year-over-year to 16.5% in Q1 2026; TTM through Mar 2026 was 7.05%, a 5201.0% decrease from a year earlier, with the FY2025 full-year figure at 50.09%, up 8760.0% from the prior year.
• EBIT Margin rose to 16.5% in Q1 2026 per PTCT's latest filing, from 43.33% in the prior quarter.
• Across five years, EBIT Margin topped out at 82.5% in Q1 2025 and bottomed at 119.67% in Q4 2022.
• The 5-year median for EBIT Margin is 37.37% (2022), against an average of 35.16%.
• Across the five-year window, EBIT Margin soared 12156 bps in 2023 and sank 7807 bps in 2024, its largest moves.
• Year by year, EBIT Margin stood at 119.67% in 2022, then surged by 102 bps to 1.9% in 2023, then slumped by 4119 bps to 76.18% in 2024, then surged by 43 bps to 43.33% in 2025, then soared by 138 bps to 16.5% in 2026.
• Per Business Quant, the three latest PTCT EBIT Margin figures stand at 16.5% (Q1 2026), 43.33% (Q4 2025), and 1.43% (Q3 2025).